Zacks Investment Research upgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a buy rating in a research note released on Thursday, Zacks.com reports. The firm currently has $3.75 price target on the biotechnology company’s stock.

According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “

Separately, Oppenheimer set a $9.00 target price on Compugen and gave the stock a buy rating in a research note on Tuesday, February 26th.

CGEN stock opened at $3.26 on Thursday. The company has a quick ratio of 4.66, a current ratio of 5.11 and a debt-to-equity ratio of 0.11. The firm has a market cap of $168.74 million, a PE ratio of -7.95 and a beta of 2.43. Compugen has a fifty-two week low of $2.00 and a fifty-two week high of $4.31.

Compugen (NASDAQ:CGEN) last issued its earnings results on Monday, May 20th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. On average, equities analysts forecast that Compugen will post -0.57 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. ARK Investment Management LLC raised its holdings in shares of Compugen by 15.8% in the 1st quarter. ARK Investment Management LLC now owns 8,229,555 shares of the biotechnology company’s stock valued at $34,070,000 after acquiring an additional 1,123,597 shares in the last quarter. Morgan Stanley raised its holdings in shares of Compugen by 7.4% in the 1st quarter. Morgan Stanley now owns 1,013,807 shares of the biotechnology company’s stock valued at $4,197,000 after acquiring an additional 69,714 shares in the last quarter. Nikko Asset Management Americas Inc. raised its holdings in shares of Compugen by 14,153.9% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 886,590 shares of the biotechnology company’s stock valued at $3,670,000 after acquiring an additional 880,370 shares in the last quarter. Taylor Frigon Capital Management LLC raised its holdings in shares of Compugen by 17.2% in the 4th quarter. Taylor Frigon Capital Management LLC now owns 690,262 shares of the biotechnology company’s stock valued at $1,498,000 after acquiring an additional 101,212 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Compugen by 31.1% in the 1st quarter. Renaissance Technologies LLC now owns 462,300 shares of the biotechnology company’s stock valued at $1,914,000 after acquiring an additional 109,700 shares in the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Compugen

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Featured Story: How is diluted EPS different from basic EPS?

Get a free copy of the Zacks research report on Compugen (CGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.